Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic agents: balancing cost, efficacy, and side effects.

V J Marder1

  • 1Department of Medicine, University of Rochester School of Medicine & Dentistry, New York.

Clinical Cardiology
|April 1, 1990
PubMed
Summary

Thrombolytic therapy offers benefits but carries risks. Optimal use depends on the condition, with acute myocardial infarction (MI) being the primary indication due to reduced mortality risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

International angiology : a journal of the International Union of Angiology·2012
Same author

Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment.

Thrombosis research·2010
Same author

Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.

Journal of thrombosis and haemostasis : JTH·2010
Same author

Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.

Journal of thrombosis and haemostasis : JTH·2009

Area of Science:

  • Cardiovascular Medicine
  • Thrombosis Research
  • Medical Economics

Background:

  • Thrombolytic therapy involves balancing benefits against risks and costs.
  • The primary threat of thrombus varies by condition: postphlebitic syndrome in deep vein thrombosis (DVT), short-term mortality in pulmonary embolism (PE), and coronary artery thrombus mortality in acute myocardial infarction (MI).

Purpose of the Study:

  • To evaluate the value of thrombolytic therapy in addition to antithrombotic approaches for DVT and PE.
  • To identify the optimal indications and treatment windows for thrombolytic therapy.

Main Methods:

  • Comparative analysis of thrombolytic therapy benefits and risks across different thrombotic conditions.
  • Review of existing literature on thrombolytic agents and non-pharmacologic interventions for acute MI.

Main Results:

  • Acute MI is the strongest indication for thrombolytic therapy due to its potential to reduce mortality.
  • Treatment windows for thrombolytic therapy vary: shortest for MI, intermediate for PE, and longest for DVT.

Conclusions:

  • The decision to use thrombolytic therapy requires careful consideration of the specific thrombotic condition and its associated risks.
  • Further research may refine the use of thrombolytic therapy in conjunction with other treatments for DVT and PE.

Related Experiment Videos